Single Antiplatelet Therapy Transition Tool for High Bleeding Risk

Clinical calculation support · Verify results before clinical use

Patient and treatment details

Use this decision aid to support, not replace, individualized post-PCI antiplatelet review.

PCIAntiplatelet review

Enter elapsed time from the most recent PCI. Decimals are allowed (for example, 1.5).

Current antiplatelet regimen

Choose the regimen the patient is taking now.

Bleeding-risk classification

Use a clinical assessment; do not infer high bleeding risk from a single symptom or this tool.

Relevant when the patient is taking DAPT or P2Y12 monotherapy.

Recurrent ischemia, suspected stent thrombosis, or clinical instability?

If present, routine abbreviated-DAPT suggestions are not appropriate without urgent specialist assessment.

Clinical context

Dual antiplatelet therapy (DAPT) reduces recurrent atherothrombotic events after acute coronary syndrome (ACS), while increasing bleeding risk. The default duration and the appropriateness of an abbreviated strategy depend on ACS presentation, PCI features, ischemic risk, bleeding risk, drug tolerance, and clinical course.

How to use this decision aid

  • Confirm high bleeding risk using a recognized framework such as ARC-HBR and review prior bleeding, anemia, renal function, age, and concomitant anticoagulation.
  • Review PCI complexity, stent-related risk, recurrent ischemia, adherence, and the exact antiplatelet agent before making a change.
  • For ACS patients who have tolerated ticagrelor-based DAPT, the 2025 ACC/AHA guideline recommends transition to ticagrelor monotherapy at least 1 month after PCI to reduce bleeding.
  • For ACS patients undergoing PCI who are at high bleeding risk, transition to single antiplatelet therapy after 1 month may be reasonable. This is not an automatic rule for every patient or every agent.
  • For ACS patients without high bleeding risk, DAPT for at least 12 months remains the default strategy unless individual circumstances warrant another approach.

Interpretation limits

This tool is a structured prompt for clinician review. It does not calculate ARC-HBR, estimate an individual patient's net clinical benefit, or determine which agent should be stopped. Evidence for early clopidogrel monotherapy after ACS is mixed; the drug choice requires clinical judgment.

References

Rao SV, O'Donoghue ML, Ruel M, et al.

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. Circulation. 2025;151:e771–e862.

doi:10.1161/CIR.0000000000001309
Valgimigli M, Bueno H, Byrne RA, et al.

2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44:3720–3826.

doi:10.1093/eurheartj/ehad191
Urban P, Mehran R, Colleran R, et al.

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. European Heart Journal. 2019;40:2632–2653.

doi:10.1093/eurheartj/ehz372
Clinical disclaimer: This decision-support tool is not a substitute for current guidelines, local protocols, or specialist judgment. Do not stop or change antiplatelet therapy solely on the basis of this output. Any active major bleeding, suspected stent thrombosis, recurrent ischemia, or clinical deterioration requires urgent assessment.